Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 220

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 220
---
 are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

83

ITEM 9B. OTHER INFORMATION

Rule 10b5-1 Trading PlansThe adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended December 31, 2024, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) (Rule 10b5-1 Plan), were as follows: 

      Rule 10b5-1 Trading Plan
       
      Aggregate # of

      Provides for
       
      Securities to be

      Name
       
      Title
       
      Action
       
      Date Adopted
       
      Expiration Date
       
      Purchase/Sale
       
      Purchased/Sold (b)

      David C. Stump
       
      Director
       
      Adoption
       
      11/21/2024
       
      6/1/2026
       
      Sale
       
      37,500

      Stephen Pakola, M.D.
       
      Executive Vice President, Chief Medical Officer
       
      Adoption
       
      12/20/2024
       
      12/31/2025
       
      Sale
       
      260,368

      Entities affiliated with Allan M. Fox (a)
       
      Director
       
      Adoption
       
      12/21/2024
       
      3/31/2027
       
      Sale
       
      1,441,231

      Patrick J. Christmas
       
      Executive Vice President, Chief Legal Officer
       
      Adoption
       
      12